Log in
NASDAQ:IDYA

IDEAYA Biosciences Stock Forecast, Price & News

$13.56
+0.20 (+1.50 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.50
Now: $13.56
$13.71
50-Day Range
$12.17
MA: $13.16
$14.20
52-Week Range
$2.95
Now: $13.56
$19.97
Volume38,548 shs
Average Volume160,355 shs
Market Capitalization$394.19 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IDYA
CUSIPN/A
CIKN/A
Phone(650) 443-6209
Employees56

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.94 per share

Profitability

Net Income$-41,970,000.00

Miscellaneous

Market Cap$394.19 million
Next Earnings Date3/23/2021 (Estimated)
OptionableNot Optionable
$13.56
+0.20 (+1.50 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDYA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEAYA Biosciences (NASDAQ:IDYA) Frequently Asked Questions

How has IDEAYA Biosciences' stock price been impacted by Coronavirus?

IDEAYA Biosciences' stock was trading at $4.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IDYA stock has increased by 179.6% and is now trading at $13.56.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of IDEAYA Biosciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IDEAYA Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IDEAYA Biosciences?

Wall Street analysts have given IDEAYA Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IDEAYA Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IDEAYA Biosciences' next earnings date?

IDEAYA Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for IDEAYA Biosciences
.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its earnings results on Tuesday, November, 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $2.93 by $3.10.
View IDEAYA Biosciences' earnings history
.

What price target have analysts set for IDYA?

6 equities research analysts have issued 1 year price targets for IDEAYA Biosciences' stock. Their forecasts range from $12.00 to $28.00. On average, they expect IDEAYA Biosciences' share price to reach $22.67 in the next twelve months. This suggests a possible upside of 67.2% from the stock's current price.
View analysts' price targets for IDEAYA Biosciences
.

Who are some of IDEAYA Biosciences' key competitors?

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), The Boeing (BA), Xeris Pharmaceuticals (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

Who are IDEAYA Biosciences' key executives?

IDEAYA Biosciences' management team includes the following people:
  • Yujiro S. Hata, President, Chief Executive Officer & Director
  • Paul A. Stone, Chief Financial Officer
  • Michael P. Dillon, Chief Scientific Officer, SVP & Head-Research
  • Mark Lackner, SVP, Head-Biology & Translational Sciences
  • Bao Truong, Vice President & Head-Regulatory Affairs

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

What is IDEAYA Biosciences' stock symbol?

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (3.98%), BlackRock Inc. (3.08%), State Street Corp (0.72%), Platinum Investment Management Ltd. (0.67%), Squarepoint Ops LLC (0.23%) and Charles Schwab Investment Management Inc. (0.14%). Company insiders that own IDEAYA Biosciences stock include Alexandria Venture Investments, Bvf Partners L P/Il, Jason Throne, Mark Lackner, Paul A Stone, Timothy M Shannon, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends for IDEAYA Biosciences
.

Which major investors are selling IDEAYA Biosciences stock?

IDYA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have sold IDEAYA Biosciences company stock in the last year include Jason Throne, Mark Lackner, Paul A Stone, and Ventures Iv LP 5Am.
View insider buying and selling activity for IDEAYA Biosciences
.

Which major investors are buying IDEAYA Biosciences stock?

IDYA stock was purchased by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., BlackRock Inc., Point72 Asset Management L.P., Squarepoint Ops LLC, State Street Corp, California Public Employees Retirement System, Massachusetts Financial Services Co. MA, and Acadian Asset Management LLC. Company insiders that have bought IDEAYA Biosciences stock in the last two years include Alexandria Venture Investments, Bvf Partners L P/Il, Paul A Stone, Timothy M Shannon, and Value Fund L P Biotechnology.
View insider buying and selling activity for IDEAYA Biosciences
.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IDEAYA Biosciences' stock price today?

One share of IDYA stock can currently be purchased for approximately $13.56.

How big of a company is IDEAYA Biosciences?

IDEAYA Biosciences has a market capitalization of $394.19 million. The company earns $-41,970,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. IDEAYA Biosciences employs 56 workers across the globe.

What is IDEAYA Biosciences' official website?

The official website for IDEAYA Biosciences is www.ideayabio.com.

How can I contact IDEAYA Biosciences?

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 443-6209 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.